Basaglar, Levemir & Tresiba Prior Authorization Request Form (Page 1 of 2) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY HAVE BARCODES.

This form may be faxed to 844-403-1029.

Member Information (required)			P	Provider Information (required)			
Member Name:			Provider Name	Provider Name:			
Insurance ID#:			NPI#:	NPI#: Specialty:			
Date of Birth:			Office Phone:				
Street Address:			Office Fax:				
City:	State:	ZIP:	Office Street A	Office Street Address:			
Phone:			City:	: State: ZIF		ZIP:	
		Medication	Information	(required)			
Medication Name:			Strength:			n:	
			Directions for	Directions for Use:			
Clinical Information (required)							
1. Select the diagnosis below:							
 Type 1 diabetes mellitus Type 2 diabetes mellitus 							
Other diagnosis: ICD-10 Code:							
2. Has the patient demonstrated a failure with or intolerance to a majority (two or more in a class with at							
least two alternatives or one in a class with only one alternative) of the preferred formulary/preferred							
drug list alternatives (e.g., Lantus or Toujeo) for the given diagnosis for at least six weeks? If yes, please submit documentation including medication(s) tried, dates of trial(s) and reason for							
treatment failure(s):							
3. Does the patient have a documented contraindication to the listed formulary alternatives (e.g., Lantus,							
Toujeo)?							
If yes, please submit documentation including medication(s) name(s) and contraindication:							
4. Has the patient had an adverse reaction to OR would be reasonably expected to have an adverse						□ Yes □ No	
reaction to a majority (two or more in a class with at least two alternatives or one in a class with only one							
alternative) of the listed formulary agents used for the requested indication (e.g., Lantus, Toujeo)?							
lf yes, please su	ıbmit document	ation including medicati	ion(s) name(s) and	l adverse reactior	n(s):		
5. Does the patient have a clinical condition for which there is no listed formulary agent to treat the							
condition based on published guidelines or clinical literature (e.g., Lantus, Toujeo)?							
If yes, please submit documentation including the clinical condition:							
						-	
6. Is the drug being prescribed within the manufacturer's published dosing guidelines or does the dose fall							
within dosing guidelines found in accepted compendia or current literature (e.g., package insert, AHFS, Micromedex, current accepted guidelines, etc.)?							
		ga					

This document - and others if attached - contains information that is privileged, confidential and/or may contain protected health information (PHI). The provider named above is required by applicable law to safeguard PHI. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately. Office use only: Basaglar-Levemir-Tresiba_2019Dec

Basaglar, Levemir & Tresiba Prior Authorization Request Form (Page 2 of 2)

Information on this form is accurate as of this date.

Prescriber's Signature:	Date:

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

<u>Please note:</u> This request may be denied unless all required information is received. For more information about the prior authorization process, please contact us at 855-811-2218. Monday – Friday: 8 a.m. to 1 a.m. Eastern, and Saturday: 9 a.m. to 6 p.m. Eastern

This document – and others if attached – contains information that is privileged, confidential and/or may contain protected health information (PHI). The provider named above is required by applicable law to safeguard PHI. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.** Office use only: Basaglar-Levemir-Tresiba_2019Dec